Reaction

Skin Hypertrophy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,765 reports · 86 co-occurring drugs

As of the last recalculation, Skin Hypertrophy appears in 2,765 FAERS reports alongside 86 co-occurring drug terms. The strongest observed disproportionality signal is EPOETIN ALFA (PRR 125.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Epoetin Alfa	185	125.9	127.9
Paricalcitol	62	33.8	33.9
Iron Sucrose	41	32.8	33.0
Quinine	28	24.8	24.9
Erythropoietin	48	17.9	17.9
Calcitriol	45	17.0	17.0
Calcitriol Capsules 0.25 Mcg	44	16.8	16.8
Calcitriol Capsules 0.5 Mcg	44	16.8	16.8
Sorafenib	44	16.2	16.2
Regorafenib	19	12.4	12.4
Clobetasol Propionate Ointment Usp, 0.05%	16	11.8	11.8
Clobetasol Propionate	16	11.7	11.7
Cimetidine	13	10.2	10.2
Cinacalcet Hydrochloride	61	10.1	10.1
Darbepoetin Alfa	67	9.6	9.6
Clonidine	62	9.3	9.3
Sevelamer Carbonate	14	9.2	9.2
Ribociclib	36	8.7	8.7
Nifedipine	53	8.6	8.6
Enalapril Maleate	28	8.6	8.6
Asfotase Alfa	11	8.3	8.3
Captopril	10	7.9	7.9
Metoroprolol Tartrate	67	7.8	7.8
Dronabinol	8	7.5	7.5
Indomethacin	13	7.4	7.4
Felodipine Extended-Release Tablets	11	7.3	7.3
Felodipine	11	7.3	7.3
Valganciclovir	18	7.2	7.2
Valganciclovir Hydrochloride	18	7.2	7.2
Sunitinib Malate	37	7.2	7.2
Ketoconazole Foam	14	7.2	7.2
Ketoconazole Cream, 2%	14	7.1	7.1
Ketoconazole	16	7.0	7.0
Sodium Bicarbonate	21	6.8	6.8
Sodium Bicarbonate Injection,	21	6.8	6.8
Diltiazem Hydrochloride	31	6.8	6.8
Metolazone	10	6.7	6.7
Mometasone	16	6.6	6.6
Secukinumab	134	6.5	6.5
Anastrozole Tablets	18	6.3	6.4
Crisaborole	8	6.3	6.3
Vemurafenib	10	6.3	6.3
Busulfan	13	6.2	6.2
Labetalol	11	6.2	6.2
Rifampin	12	6.2	6.2
Triamcinolone Acetonide Ointment Usp, 0.05%	19	6.1	6.1
Dabrafenib	17	6.1	6.1
Ritonavir 100 Mg	12	6.1	6.1
Amlodipine Besylate	112	6.0	6.0
Nemolizumab-Ilto	10	5.9	5.9
Doxazosin Mesylate	28	5.9	5.9
Losartan Potassium	60	5.8	5.8
Mycophenolate Mofetil	101	5.8	5.8
Mycophenolate Mofetil Hydrochloride	101	5.8	5.8
Enalapril	40	5.5	5.5
Daspone	7	5.4	5.4
Dapsone Gel, 5%	7	5.4	5.4
Extended Phenytoin Sodium	12	5.4	5.4
Doxazosin	20	5.4	5.4
Anastrozole	24	5.0	5.0
Warfarin Sodium	30	4.9	4.9
Imatinib	11	4.7	4.7
Triamcinolone Acetonide	19	4.7	4.7
Nintedanib	19	4.6	4.6
Cabozantinib	29	4.6	4.6
Lapatinib	9	4.4	4.4
Minoxidil Foam 5% (Womens)	18	4.1	4.1
Insulin Human	21	4.0	4.0
Timolol	6	3.7	3.7
Minoxidil	22	3.7	3.7
Pegvaliase-Pqpz	4	3.7	3.7
Ado-Trastuzumab Emtansine	4	3.6	3.6
Imatinib Mesylate	13	3.5	3.5
Pertuzumab	12	3.3	3.3
Omalizumab	37	3.3	3.3
Dupilumab	191	3.1	3.1
Conjugated Estrogens And Medroxyprogesterone Acetate	9	2.9	2.9
Risankizumab-Rzaa	27	2.5	2.5
Liraglutide	16	2.4	2.4
Abaloparatide	9	2.3	2.3
Encorafenib	3	2.3	2.3
Palbociclib	25	2.0	2.0
Etonogestrel	8	1.3	1.3
Adapalene	25	1.0	1.0
Apremilast	20	1.0	1.0
Salicylic Acid	5	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.